Experimental MS Drug Nearly Eliminates Disease Activity

PHOENIX — Frexalimab, a second-generation anti-CD40 ligand monoclonal antibody provides extended tight control of multiple sclerosis (MS) whether measured by relapse or brain imaging at 2-year follow-up, results of an open-label extension (OLE) of a phase 2 trial showed. “At week 96, there was almost complete suppression of new gadolinium-enhancing lesions with very similar pattern …